Celltrion Healthcare receives EC approval for the first high concentration, low-volume and citrate-free biosimilar adalimumab, Y
Celltrion Healthcare announced the European Commission (EC) has granted marketing authorisation for Yuflyma™ (CT-P17), an adalimumab biosimilar, across all thirteen intended indications for the treatment of multiple chronic inflammatory diseases.